Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6152328rdf:typepubmed:Citationlld:pubmed
pubmed-article:6152328lifeskim:mentionsumls-concept:C0007226lld:lifeskim
pubmed-article:6152328lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:6152328lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:6152328lifeskim:mentionsumls-concept:C0007610lld:lifeskim
pubmed-article:6152328lifeskim:mentionsumls-concept:C0013355lld:lifeskim
pubmed-article:6152328lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:6152328pubmed:issue1-3lld:pubmed
pubmed-article:6152328pubmed:dateCreated1985-4-26lld:pubmed
pubmed-article:6152328pubmed:abstractTextMultiple forms of Dynorphin A (Dyn A) are present in cardiovascular nuclei in the hypothalamus, along with kappa-opiate receptors. To study the potential role of Dyn A in cardiovascular regulation, various Dyn A species [Dyn A-(1-8; 1-13; 1-17)] were microinjected into the preoptic nucleus (POM) of the anesthetized rat. Dyn A-(1-17) was tenfold more potent than Dyn A-(1-13), and over 100-fold more potent than Dyn A-(1-8) in reducing systemic blood pressure. High doses of Dyn A-(1-17) (6 nmoles) produced shock with severe bradycardia and bradypnea. These data suggest that Dyn A may be an endogenous modulator of cardiorespiratory variables in the anteroventral hypothalamus, and demonstrate that the larger fragments of the peptide are more active in eliciting central cardiorespiratory activity in this region.lld:pubmed
pubmed-article:6152328pubmed:languageenglld:pubmed
pubmed-article:6152328pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6152328pubmed:citationSubsetIMlld:pubmed
pubmed-article:6152328pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6152328pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6152328pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6152328pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6152328pubmed:statusMEDLINElld:pubmed
pubmed-article:6152328pubmed:monthDeclld:pubmed
pubmed-article:6152328pubmed:issn0143-4179lld:pubmed
pubmed-article:6152328pubmed:authorpubmed-author:FeuersteinGGlld:pubmed
pubmed-article:6152328pubmed:authorpubmed-author:FadenA IAIlld:pubmed
pubmed-article:6152328pubmed:issnTypePrintlld:pubmed
pubmed-article:6152328pubmed:volume5lld:pubmed
pubmed-article:6152328pubmed:ownerNLMlld:pubmed
pubmed-article:6152328pubmed:authorsCompleteYlld:pubmed
pubmed-article:6152328pubmed:pagination295-8lld:pubmed
pubmed-article:6152328pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6152328pubmed:meshHeadingpubmed-meshheading:6152328-...lld:pubmed
pubmed-article:6152328pubmed:meshHeadingpubmed-meshheading:6152328-...lld:pubmed
pubmed-article:6152328pubmed:meshHeadingpubmed-meshheading:6152328-...lld:pubmed
pubmed-article:6152328pubmed:meshHeadingpubmed-meshheading:6152328-...lld:pubmed
pubmed-article:6152328pubmed:meshHeadingpubmed-meshheading:6152328-...lld:pubmed
pubmed-article:6152328pubmed:meshHeadingpubmed-meshheading:6152328-...lld:pubmed
pubmed-article:6152328pubmed:meshHeadingpubmed-meshheading:6152328-...lld:pubmed
pubmed-article:6152328pubmed:meshHeadingpubmed-meshheading:6152328-...lld:pubmed
pubmed-article:6152328pubmed:meshHeadingpubmed-meshheading:6152328-...lld:pubmed
pubmed-article:6152328pubmed:year1984lld:pubmed
pubmed-article:6152328pubmed:articleTitleCardiovascular effects of dynorphin A-(1-8), dynorphin A-(1-13) and dynorphin A-(1-17) microinjected into the preoptic medialis nucleus of the rat.lld:pubmed
pubmed-article:6152328pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6152328pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:6152328pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6152328lld:pubmed